Elanco Animal Health Incorporated (ELAN) on Thursday said it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro CA1 for the treatment of infestations caused by New World screwworm larvae in dogs.
The conditional approval was based on a study evaluating the efficacy of lotilaner, the active ingredient in Credelio Quattro CA1, against New World screwworm. Published in Parasites & Vectors, the study found that oral administration of lotilaner at the minimum recommended dosage was 100% effective against Cochliomyia hominivorax larvae within 24 hours in naturally infested dogs.
According to the U.S. Department of Agriculture, 14 cases of New World screwworm have been reported within 400 miles of the U.S.-Mexico border, all linked to cattle movement.
ELAN shares were up more than 2% in pre-market after closing at $22,08, down 1.82%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.